GET DAILY SIGNALSSotera Health (SHC) Reports +4.4% Revenue Growth in Q3 2026 Earnings Beat
Key Takeaways
- Third-quarter 2026 revenue rose 4.4% year over year to $324.9 million, topping consensus estimates of roughly $319.7 million.
- Adjusted earnings per share (EPS) of $0.29 beat the $0.27 consensus and climbed 12% versus the prior-year period.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) increased 3.9% to $170.7 million, with margins expanding sequentially to 52.5%.
- Sterigenics grew 8.2% in constant currency, while Nordion declined 11.5% on expected Cobalt-60 harvest timing.
- Management reaffirmed its full-year 2026 outlook but flagged softening medical device demand, particularly in Europe.
Why These Results Matter
Sotera Health holds a mission-critical role in the healthcare supply chain through its Sterigenics, Nordion, and Nelson Labs segments, offering sterilization, lab testing, and advisory services. Its performance provides a timely read on medical device and pharmaceutical production levels. Coming after a strong second quarter where the company raised its full-year outlook, the latest report drew close scrutiny on whether growth at Sterigenics and Nelson Labs would hold and whether any demand weakness would surface. The numbers delivered another beat, yet the more cautious commentary on the fourth quarter shifted attention toward the durability of that momentum.
Breaking Down the Reported Numbers
Sotera Health posted third-quarter 2026 net revenues of $324.9 million, up 4.4% both as reported and in constant currency. GAAP net income reached $58 million, or $0.20 per diluted share. Adjusted EPS advanced 12% year over year to $0.29, exceeding the $0.27 consensus, while adjusted EBITDA rose 3.9% to $170.7 million, just above the roughly $167.8 million expected. The adjusted EBITDA margin widened nearly 100 basis points sequentially to 52.5%.
Segment results showed Sterigenics revenue at $209 million, up 8.5% as reported and 8.2% in constant currency, driven by 4.8% pricing gains plus favorable volume and mix. Nelson Labs revenue increased 8.8% to $61 million, or 9.2% in constant currency, aided by stronger expert advisory activity. Nordion revenue fell 12.4% to $55 million due to the planned timing of Cobalt-60 harvests, although segment income margin improved 71 basis points to 61.3%.
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Responded
The clean top- and bottom-line beat prompted an initially positive reaction that quickly turned more measured. Having raised its constant-currency outlook in the prior quarter, the company faced expectations for further upward revisions. Instead, management reaffirmed guidance and highlighted softening medical device demand that emerged mid-to-late in the quarter, describing it as broad-based. A trimmed reported revenue range tied to a smaller foreign-exchange tailwind added to the tempered tone. The result was a solid beat tempered by forward caution, leaving investor sentiment mixed.
Looking Ahead: Guidance and What to Watch
The key question now centers on whether the described medical device softness represents a short pause or the beginning of a wider slowdown. Sotera Health guided Sterigenics to roughly 6% constant-currency revenue growth in the fourth quarter, below the 8.2% achieved in the third, and indicated it does not anticipate the usual seasonal lift. Investors will want to monitor commentary from major medical device customers and whether European weakness extends elsewhere.
Nelson Labs is expected to ease from its robust third-quarter pace, while Nordion’s results will remain tied to Cobalt-60 harvest timing. On the balance sheet, net leverage improved to 2.9x within the long-term target range, and a Moody’s upgrade in early October bolstered the credit profile. Capital expenditures are projected at $200 million to $225 million for 2026, with a notable decline anticipated in 2027, making free cash flow conversion an important metric. Management kept its full-year 2026 adjusted EPS guidance of $0.95 to $1.01 intact.
From what I see, these forward details deserve close attention in the weeks ahead.
Exploring AI Tools for Earnings Analysis
When reviewing results like these, I often rely on Tickeron’s AI tools to cross-check patterns across the healthcare services space and identify comparable setups. One resource I turn to regularly is the AI Screener, which lets me apply customizable filters for fundamentals, technical signals, and industry trends in a single view. It has helped surface context that complements traditional earnings reads without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SHC's RSI Indicator remains in oversold zone for 2 days
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where SHC advanced for three days, in 187 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
SHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SHC as a result. In 60 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for SHC turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 26 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
SHC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for SHC entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. SHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.804) is normal, around the industry mean (66.084). P/E Ratio (27.842) is within average values for comparable stocks, (2.723). Projected Growth (PEG Ratio) (1.313) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties